A New Diabetes Drug Under Investigation Might Have Fewer Side Effects
One of the most important things for a diabetic is to be able to take their insulin and actually have it work. Unfortunately, for many that is not the case. There are currently medications on the market including Actos but the side effects, such as cancer, are a great concern.
Scientists have been using mice in experimental programs with a new medication that may be able to counter react the resistance in taking insulin and in the treatment of diabetes altogether.
A receptor gives the insulin the way to do its job; however, the side effects of the drugs to make that happen are severe. The new drug that is currently being tested is to help insulin resistance by activating this same receptor but with fewer side effects that the current drugs on the market have.
Many patients with diabetes and type 2 diabetes do not want to take the medication that is prescribed due to the side effects associated with it. Not only does this make the patient sick but it can also shorten their life span. Unfortunately, with the side effects that are associated with the current medications, many patients feel that there is a risk no matter what they do. When using the mice in lab tests on the new drug, it has been found that insulin resistance is treated as well as the diabetes.
It is important that medications are able to penetrate the cells in order to be effective. Although the new drug being tested did not activate the PPARy in cells like other medications, it latched onto a different part of the cell instead.
The mitochondrion is a section of a cell that produces energy and this is the section where the new drug works. Not only has it been effective in treating the insulin resistance but it has also shown other benefits including anti-inflammatory benefits and improved insulin resistance in the fat, liver and muscle cells.
Although this may not seem like a giant leap for the medical community to the average person, it is actually a wonderful leap in the right direction. There are still many steps to be taken before the drug can be considered for the market. Many tests still need to be done in order to find out what makes this drug tick. For example, they need to work with the cells and the drug to find the proteins that make it work.
They need to know why it clings to the mitochondrial membrane, can still do its job plus have the other added benefits. If they can avoid the PPARy pathway altogether, get the results they are looking for and have fewer side effects for the patients taking the medication, they will have struck gold.
Naturally, scientists are anxious to learn everything that they can about the new drug including its effects on metabolism. Of course, these tests will be done years from now as they are in the beginning to the middle stages with the current testing and investigation.